Search results for "Highlights"
Fenofibrate cost-effective for preventing diabetic retinopathy progression
In diabetes patients with mild background retinopathy in both eyes or observable background retinopathy or maculopathy in one or both eyes, treatment with fenofibrate reduced the need for any referable diabetic retinopathy or treatment by 4.4% over two years, an analysis of a randomized trial found.
https://diabetes.acponline.org/archives/2025/07/11/3.htm
11 Jul 2025
Mifepristone improved diabetes control in hypercortisolism, industry trial finds
Patients with poorly controlled type 2 diabetes and hypercortisolism assigned to mifepristone versus placebo had lower HbA1c levels and greater reductions in body mass index and waist circumference at 24 weeks, although adverse events were common.
https://diabetes.acponline.org/archives/2025/07/11/2.htm
11 Jul 2025
Semaglutide associated with lower stroke risk than empagliflozin
An analysis of observational data found better outcomes with semaglutide than empagliflozin, particularly in patients younger than age 65 years. Outcomes with dulaglutide were similar to those with empagliflozin.
https://diabetes.acponline.org/archives/2025/07/11/1.htm
11 Jul 2025
Diabetes progression linked with increased risk of kidney cancer
Kidney cancer risk was significantly higher in patients with prolonged duration of diabetes, those with diabetic retinopathy or nephropathy, and those with poor glycemic control, a cohort study in South Korea found.
https://diabetes.acponline.org/archives/2025/06/13/3.htm
13 Jun 2025
Renal outcomes better with finerenone plus empagliflozin in type 2 diabetes and CKD
Patients with type 2 diabetes and chronic kidney disease (CKD) had a greater reduction in urinary albumin-to-creatinine ratio if they took finerenone plus empagliflozin versus either drug alone, an industry trial found.
https://diabetes.acponline.org/archives/2025/06/13/2.htm
13 Jun 2025
ADA consensus report calls for MASLD, liver fibrosis screening in type 2 diabetes
A two-tier system for stratifying patients based on their risk of metabolic dysfunction-associated steatotic liver disease (MASLD) was recommended by the American Diabetes Association (ADA).
https://diabetes.acponline.org/archives/2025/06/13/1.htm
13 Jun 2025
Studies examine prescribing patterns, access issues with newer diabetes drug classes
Use of tirzepatide, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors increased sharply in the U.S. from 2021 to 2023, one study found, while another noted inequities in availability of newer medications for type 2 diabetes.
https://diabetes.acponline.org/archives/2025/05/09/3.htm
9 May 2025
Standard care noninferior to acellular, cellular matrix products for diabetic foot ulcers
Researchers found no clinically significant differences in ulcer healing between the treatment types but found that acellular matrix products were more cost-effective than cellular matrix products and should thus be considered if standard care fails.
https://diabetes.acponline.org/archives/2025/05/09/2.htm
9 May 2025
Alternative measures didn't help in conditions thought to affect accuracy of HbA1c level
Using fructosamine or glycated albumin did not improve overall accuracy of glycemic measurement in an African population overall or in patients with sickle cell trait, anemia, or renal impairment, according to a comparison of these measures with HbA1c level and continuous glucose monitoring.
https://diabetes.acponline.org/archives/2025/05/09/1.htm
9 May 2025
Gastric bypass increased diabetes remission versus sleeve gastrectomy, small trial finds
At five years after gastric bypass, half of patients with type 2 diabetes and obesity had an HbA1c level less than 6%, compared to 20% of those randomized to sleeve gastrectomy, according to a secondary analysis of a Norwegian trial.
https://diabetes.acponline.org/archives/2025/04/11/3.htm
11 Apr 2025
Switching to tirzepatide improves outcomes vs. escalating dulaglutide in type 2 diabetes
An industry-funded randomized trial found that switching to tirzepatide after inadequate response to dulaglutide led to significant additional reductions in HbA1c levels and weight at 40 weeks compared with increasing the dulaglutide dose.
https://diabetes.acponline.org/archives/2025/04/11/2.htm
11 Apr 2025
Older patients have increased hypoglycemia risk soon after beta-blocker initiation
Hypoglycemia risk nearly doubled in the immediate period after initiation of beta-blockers compared with long-standing use, and the risk was higher in patients who were also taking insulin, a Canadian study of older patients with type 2 diabetes found.
https://diabetes.acponline.org/archives/2025/04/11/1.htm
11 Apr 2025
Studies show potential sequelae on diabetic eye from cataract surgery, GLP-1 use
One retrospective study found that progression to proliferative diabetic retinopathy was more likely after cataract surgery, while another showed that a modest increase in the risk of nonarteritic anterior ischemic optic neuropathy may be associated with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide.
https://diabetes.acponline.org/archives/2025/03/14/3.htm
14 Mar 2025
One-hour glucose tolerance test accurate, convenient for postpartum assessment
The one-hour test identified dysglycemia in 60 of 70 patients who were also diagnosed by their two-hour glucose value, as well as 96 additional patients, a single-center Canadian study found.
https://diabetes.acponline.org/archives/2025/03/14/2.htm
14 Mar 2025
Model could help select initial glucose-lowering therapy for type 2 diabetes
Age, duration of diabetes, sex, baseline body mass index, and baseline levels of HbA1c, estimated glomerular filtration rate, cholesterol levels, and alanine aminotransferase were used to predict the effectiveness of five classes of diabetes drugs.
https://diabetes.acponline.org/archives/2025/03/14/1.htm
14 Mar 2025
SGLT-2 inhibitors, GLP-1 receptor agonists lower COPD exacerbation risk
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists were associated with significant reductions in severe chronic obstructive pulmonary disease (COPD) exacerbations compared with dipeptidyl peptidase-4 inhibitors, an observational study found.
https://diabetes.acponline.org/archives/2025/02/14/3.htm
14 Feb 2025
Micronutrient deficiencies, especially vitamin D, common in type 2 diabetes
Approximately 45% of patients with type 2 diabetes were deficient in multiple micronutrients, with vitamin D deficiency the most common at approximately 61%, a meta-analysis of 132 studies found.
https://diabetes.acponline.org/archives/2025/02/14/2.htm
14 Feb 2025
GLP-1 receptor agonists show effects on substance disorders, infections
Researchers should examine the effects of glucagon-like peptide 1 (GLP-1) receptor agonists on multiple diseases, according to the authors of a systematic review that looked at 175 health outcomes in patients taking diabetes medications.
https://diabetes.acponline.org/archives/2025/02/14/1.htm
14 Feb 2025
U.K. consensus statement targets potential barriers to CGM use
Primary care teams face a critical need for education, training, and resources such as electronic health record integration to increase use of continuous glucose monitoring (CGM) in type 2 diabetes, an industry-funded consensus statement said.
https://diabetes.acponline.org/archives/2025/01/10/3.htm
10 Jan 2025
Trial supports insulin as first-line treatment for gestational diabetes
Metformin plus glyburide as needed did not meet criteria for noninferiority to insulin on the outcome of the proportion of infants born large for gestational age, a multicenter trial of 820 patients in the Netherlands found.
https://diabetes.acponline.org/archives/2025/01/10/2.htm
10 Jan 2025